Ultragenyx Reports Fourth Quarter and Full Year 2017 Financial Results and Corporate Update

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. WCN

6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Ultragenyx Pharma (RARE) PT Lowered to $70 at Baird; Multiple Milestones Ahead

February 21, 2018 6:52 AM EST

Baird lowered its price target on Ultragenyx Pharma (NASDAQ: RARE) to $70.00 (from $80.00) while maintaining an Outperform rating.

Analyst Michael Ulz notes building momentum with multiple commercial and clinical milestones in 2018.

"Notable catalysts remain on track for UX007, including potential for... More

February 20, 2018 4:12 PM EST

Ultragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($1.89), $0.10 better than the analyst estimate of ($1.99).

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

... More